Skip to main content

Pharmacokinetic Modulation with Particulate Drug Formulations

  • Chapter

Keywords

  • Drug Delivery
  • Drug Carrier
  • Boron Neutron Capture Therapy
  • Target Drug Delivery System
  • Parallel Artificial Membrane Permeability Assay

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-1-4020-5041-1_8
  • Chapter length: 26 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   149.00
Price excludes VAT (USA)
  • ISBN: 978-1-4020-5041-1
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   199.99
Price excludes VAT (USA)
Hardcover Book
USD   249.99
Price excludes VAT (USA)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adler-Moore J, Proffitt RT. 2002. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J. Antimicrob. Chemother. 49: 21-30.

    CAS  PubMed  Google Scholar 

  2. Agrawal AK, Gupta CM. 2000. Tufsin-bearing liposomes in treatment of macrophage-based infections. Adv. Drug Deliv. Rev. 41: 135-46.

    CAS  PubMed  Google Scholar 

  3. Ahl PL, Bhata SK, Meers SK, Roberts P, Stevens R, et al., 1997. Enhancement of the in vivo circulation lifetime of L-a-distearoylphosphatidylcholine liposomes: importance  of liposomal aggregation versus complement opsonization. Biochim. Biophys. Acta 1239: 370-82.

    Google Scholar 

  4. Allen TM. 1998. Oncologic agents in sterically stabilized liposomes: basic considerations. In Long-circulating liposomes: old drugs, new therapeutics., ed. MC Woodle, G Storm, pp. 19-28. Austin TX USA: Landes Bioscience.

    Google Scholar 

  5. Allen TM, Menezes DLd, Hansen CB, Moase EH. 1998. Stealth liposomes for the targeting of drug in cancer therapy. Targeting Drugs 6: 61-75.

    Google Scholar 

  6. Alving NM, Wassef CR. 1993. Complement-dependent phagocytosis of liposomes. Chem Phys Lipids 64: 239-46.

    PubMed  Google Scholar 

  7. Amin K, Wasan KM, Albercht RM, Heath TD. 2002. Cell association of liposomes with high fluid anionic phospholipid content is mediated specifically by LDL and its receptor, LDLr. J. Pharmaceut. Sci. 91: 1233-44.

    CAS  Google Scholar 

  8. Aoki H, Fujita M, Sun C, Fuji K, Miyajima K. 1997. High-efficiency entrapment of superoxide dismutase into cationic liposomes containing synthetic aminoglycolipid. Chem Pharm Bull 45: 1327-31.

    CAS  PubMed  Google Scholar 

  9. Avdeef A, Testa B. 2002. Physicochemical profiling in drug research: a brief survey of the state-of-the-art of experimental techniques. Cell. Mol. Life Sci. 59: 1681-9.

    CAS  PubMed  Google Scholar 

  10. Baczynska D, Widerak K, Ugorski M, Langner M. 2001. Surface charge and the association of liposomes with colon carcinoma cells. Z. Naturforsch. 56c: 872-7.

    Google Scholar 

  11. Bakan DA, Weichert JP, Longino MA, Counsell RE. 2000. Polyiodinated triglyceride lipid emulsions for use as hepatoselective contrast agents in CT. Investigative Radiol. 35: 158-69.

    CAS  Google Scholar 

  12. Bally MB, Lim H, Cullis PR, Mayer LD. 1998. Controling the drug delivery attributes of lipid-based drug formulations. J Liposome Res 8: 299-335.

    CAS  Google Scholar 

  13. Barenholz Y. 2001. Liposome application: problems and prospects. Curr. Opin. Coll. Interface Sci. 6: 66-77.

    CAS  Google Scholar 

  14. Barry BW. 2002. Drug delivery routes in skin: a novel approach. Adv. Drug Deliv. Rev. 54: S31-S40.

    CAS  PubMed  Google Scholar 

  15. Behr JP. 1997. The proton sponge: a trick to enter cells the viruses did not think of. Chimia 51: 27-30.

    Google Scholar 

  16. Bestman-Smith J, Desormeaux A, Tremblay MJ, Bergeron MG. 2000. Targeting cell- free HIV and virally-infected cells with anti-HLA-DR immunoliposomes containing amphotericin B. AIDS 14: 2457-65.

    CAS  PubMed  Google Scholar 

  17. Blau S, Jubeh TT, Haupt SM, Rubinstein A. 2000. Drug targeting by surface cationization. Crit. Rev. Therapeut. Drug Carrier Systems 17: 425-65.

    CAS  Google Scholar 

  18. Boswell GW, Buell D, Bekersky I. 1998. AmBisome (liposomal Amphotericin B): a comparative review. J Clinical Pharmacol 38: 583-92.

    CAS  Google Scholar 

  19. Brannon-Peppas L, Blanchette JO. 2004. Nanoparticles and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 56: 1649-59.

    CAS  PubMed  Google Scholar 

  20. Brokx RD, Bisland SK, Gariepy J. 2002. Designing peptide scoffolds as drug delivery vehicles. J. Controlled Release 78: 115-23.

    CAS  Google Scholar 

  21. Brouwers AH, de-Jong DJ, Dams ETM, Oyen WJG, Boerman OC, et al., 2000. Tc-99m-PEG-liposomes for the evaluation of colitis in crohn’s disease. J. Drug Targeting 8: 225-33.

    CAS  Google Scholar 

  22. Brown KC. 2000. New approaches for cell-specific targeting: identification of cell selective peptides from combinatorial libraries. Curr. Opin. Chem. Biol. 4: 16-21.

    CAS  PubMed  Google Scholar 

  23. Cammas S, Kataoka K. 1996. Site specific drug-carriers: polymeric micelles as high potental vehicles for biologically active molecules. In Solvents and self-organization of polymers, ed. SE Webber, pp. 83-113. Amsterdam: Kluwer Academic Publishers.

    Google Scholar 

  24. Campbell RB, Fukumura D, Brown EB, Mazzola LM, Izumi Y, et al., 2002. Cationic charge determines the distribution of liposomes between the vascular and extracascular compartments of tumors. Cancer Res. 62: 6831-6.

    CAS  PubMed  Google Scholar 

  25. Cansell M, Parisel C, Jozefonicz J, Letourneur D. 1999. Liposomes coated with chemically modified dextran interact with human endothelial cells. J Biomed Mater Res 44: 140-8.

    CAS  PubMed  Google Scholar 

  26. Cef B, Winterhalter M, Frederik PM, Vallner JJ, Lasic DD. 1997. Stealth liposomes: from theory to product. Adv. Drug Deliv Rev 24: 165-211.

    Google Scholar 

  27. Cevc G, Schatzlein A, Richardsen H. 2002. Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable berriers unfragmented. Evidence from double label CLSM experiments and direct size measurements. Biochim. Biophys. Acta 1564: 21-30.

    CAS  PubMed  Google Scholar 

  28. Charman WN. 2000. Lipids, lipophilic drugs, and oral drug delivery - some emerging concepts. J. Pharmaceut. Sci. 89: 967-78.

    CAS  Google Scholar 

  29. Charrois GJR, Allen TM. 2003. Rate of biodistribution of STEALTH liposomes to tumor ad skin: influence of liposome diameter and implications for toxicity and therapeutic activity. Biochim. Biophys. Acta 1609: 102-8.

    CAS  PubMed  Google Scholar 

  30. Chiu GNC, Bally MB, Mayer LD. 2001. Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol). Biochim. Biophys. ACta 1510: 56-69.

    CAS  PubMed  Google Scholar 

  31. Chiu GNC, Bally MB, Mayer LD. 2002. Effects of phosphatidylserine on membrane incorporation and surface protection properties of exchangeable poly(ethyloene glycol)-conjugated lipids. Biochim. Biophys. Acta 1560: 37-50.

    CAS  PubMed  Google Scholar 

  32. Chiu GNC, Bally MB, Mayer LD. 2003. Targeting of antibody conjugated, phsophatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogeneis. Biochim. Biophys. Acta 1613: 115-21.

    CAS  PubMed  Google Scholar 

  33. Chow F, Benincosa LJ, Sheth SB, Wilson D, Davis CB, et al. 2002. Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans. Clin. Pharmacol. Ther. 71: 235-45.

    CAS  PubMed  Google Scholar 

  34. Chung NS, Wasan KM. 2004. Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. Adv. Drug Deliv. Rev. 56: 1315-34.

    CAS  PubMed  Google Scholar 

  35. Clark DE. 2003. In silico prediction of blood-brain barrier permeation. DDT 8: 927-33.

    CAS  PubMed  Google Scholar 

  36. Colbern GT, Hiller AJ, Musterer RS, Pegg E, Henderson IC, Working PK. 1999. Significant increase in antitumor potency of doxorubicin HCl by its encapsulation in pegylated liposomes. J. Liposome Res. 9: 523-38.

    CAS  Google Scholar 

  37. Corvo ML, Boerman OC, Oyen WJG, Bloois LV, Cruz MEM, et al., 1999. Intravenous administration of superoxide dismutase entrapped in long circulating liposomes. II. In vivo fate in a rat model of adjuvant arthritis. Biochem. Biophys. Acta 1419: 325-34.

    CAS  PubMed  Google Scholar 

  38. Crommelin DJA, van-Resen AJML, Wauben MHM, Storm G. 1999. Liposomes in autoimmune diseases: selected applications in immunotherapy and inflammation detection. J. Controlled Release 62: 245-51.

    CAS  Google Scholar 

  39. Davidsen J, Jorgensen K, Andersen TL, Mouritsen OG. 2003. Secreted phospholipase A2 as a new enzymatioc trigger nechanism for localised liposomal drug release and absorption in diseased tissue. Biochi. Biophys. Acta 1609: 95-101.

    CAS  Google Scholar 

  40. Delepine P, Guillaume C, Floch V, Loisel S, Yaouanc JJ, et al., 2000. Cationic phosphonolipids as nonviral vectors: in vitro and in vivo applications. J. Pharmaceut. Sci. 89: 629-38.

    CAS  Google Scholar 

  41. DelRaso NJ, Foy BD, Gearhart JM, Frazier JM. 2003. Cadmium uptake kinetics in rat hepatocytes: correction for albumin binding. Toxicol. Sci. 72: 19-30.

    CAS  PubMed  Google Scholar 

  42. Derycke ASL, de-Witte PAM. 2004. Liposomes for photodynamic therapy. Adv. Drug Delivery Rev. 56: 17-30.

    CAS  Google Scholar 

  43. Desormeaux A, Bergeron MG. 1995. Targeting HIV with liposome-encapsulated antivirals. Zbl Bakt 282: 225-31.

    CAS  Google Scholar 

  44. Desormeaux A, Bergeron MG. 1998. Liposomes as drug delivery systems: a strategic approach for the treatment of HIV infection. J Drug Tarheting 6: 1-15.

    CAS  Google Scholar 

  45. Devis SS, Illum L. 1998. Drug delivery systems for challenging molecules. Int. J. Pharmaceutics 176: 1-8.

    Google Scholar 

  46. DiTizio V, Karlgard C, Lilge L, Khoury AE, Mittelman MW, DiCosmo F. 2000. Localized drug delivery using crosslinked gelatin gels containing liposomes: factors influencing liposome stability and drug release. J. Biomed. Mater. Res. 51: 96-106.

    CAS  PubMed  Google Scholar 

  47. Drumond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. 1999. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacological Rev. 51: 691-743.

    Google Scholar 

  48. Duzgunes N, Nir S. 1999. Mechanisms and kinetics of liposome-cell interactions. Adv Drug Deliv Rev 40: 3-18.

    CAS  Google Scholar 

  49. Duzgunes N, Pretzer E, Simoes S, Slepushkin V, Konopka K, et al., 1999. Liposome- mediated delivery of antiviral agents to human immunodeficiency virus-infected cells. Mol Mem Biol 16: 111-8.

    CAS  Google Scholar 

  50. Ehrhardt C, Kneuer C, Bakowsky U. 2004. Selectin - an emerging target for drug delivery. Adv. Drug. Deliv. Rev. 56: 527-49.

    CAS  PubMed  Google Scholar 

  51. El-Kareh AW, W. Secomb T. 2000. A Mathematical Model for Comparison of Bolus Injection,Continuous Infusion, and Liposomal Delivery of Doxorubicin to Tumor Cells. Neoplasia 2: 325-38.

    CAS  PubMed  Google Scholar 

  52. Foster N, Hirst BH. 2005. Exploiting receptor biology for oral vaccination with biodegradable particulates. Adv. Drug Deliv. Rev. 57: 431-50.

    CAS  PubMed  Google Scholar 

  53. Fouchecourt MO, Beliveau M, Krishnan K. 2001. Quantitative structure- pharmacokinetic relationship modeling. Sci. Total Environment 274: 125-35.

    CAS  Google Scholar 

  54. Gaber MH, Hong K, Huang SK, Papahadjopoulos D. 1995. Thermosensitive sterically stabilized liposomes: formulation and in vitro studies on mechanism of doxorubicin release by bovine serum and human plasma. Pharmaceut Res 12: 1407-16.

    CAS  Google Scholar 

  55. Gaber MH, Wu NZ, Hong K, Huang SK, Dewrist MW, Papahadjopoulos D. 1996. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int J Radiation Oncol Biol Phys 36: 1177-87.

    CAS  Google Scholar 

  56. Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. 2004. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv. Drug Deliv. Rev. 56: 1177-92.

    CAS  PubMed  Google Scholar 

  57. Garcia M, Alsina MA, Reig F, Haro I. 2000. Liposomes as vehicles for the presentation of a synthetic peptide containing an epitope of hepatitis A virus. Vaccine 18: 276-83.

    Google Scholar 

  58. Garcia-Fuentes M, Torres D, Alonso MJ. 2002. Design of lipid nanoparticles for the oral delivery of hydrophobic macromolecules. Coll. Surf. B: Biointerfaces 27: 159-68.

    Google Scholar 

  59. Gaspar MM, Martins MB, Corvo ML, Cruz MEM. 2003. Design and characterization of enzymosomes with surface-exposed superoxide dismutase. Biochim. Biophys. Acta 1609: 211-7.

    CAS  PubMed  Google Scholar 

  60. General S, Thunemann AF. 2001. pH-sensitive nanoparticles of poly(amino acid) dodecanoate complexes. Interant. J. Pharmaceut. 230: 11-24.

    CAS  Google Scholar 

  61. Gerasimov OV, Boomer JA, Qualls MM, Thompson DH. 1999. Cytosolic drug delivery using pH- and light-sensitive liposomes. Adv Drug Delivery Rev 38: 317-38.

    CAS  Google Scholar 

  62. Gershanik T, Haltner E, Lehr CM, Benita S. 2000. Charge-dependent interaction of self-emulsifying oil formulations with Caco-2 cells monolayers: binding, effects on barrier function and cytotoxicity. Intl. J. Pharmaceut. 211: 29-36.

    CAS  Google Scholar 

  63. Gould-Fogerite S, Kheiri MT, Zhang F, Wang Z, Scolpino AJ, et al., 1998. Targeting immune response induction with cocheate and liposome-based vaccines. Adv Drug Delivery Rev 32: 273-87.

    CAS  Google Scholar 

  64. Gregoriadis G, McCormack B, Morrison Y, Saffie R, Zadi B. 1998. Liposomes in drug targeting. Cell Biol.: a laboratory handbook 4: 131-40.

    Google Scholar 

  65. Gulden M, Morchel S, Seibert H. 2003. Serum albumin binding at cytotoxic concentrations of chemicals as determined with a cell proliferation assay. Toxicology Lett. 137: 159-68.

    CAS  Google Scholar 

  66. Guo LSS. 2001. Amphotericin B colloidal dispersion: an improved antifungal therapy. Adv. Drug Deliv. Rev. 47: 149-63.

    CAS  PubMed  Google Scholar 

  67. Gursoy A. 2000. Liposome-encapsulated antibiotics: physicochemical and antibacterial properties, a review. S.T.P. Pharma. Sci. 10: 285-91.

    CAS  Google Scholar 

  68. Hafez IM, Ansell S, Cullis PR. 2000. Tunable pH-sensitive liposomes composed of mixtures of cationic and anionic lipids. Biophys. J. 79: 1438-46.

    CAS  PubMed  Google Scholar 

  69. Hafez IM, Cullis PR. 2001. Role of lipid polymorphism in intracellular delivery. Adv. Drug Deliv. Rev. 47: 139-48.

    CAS  PubMed  Google Scholar 

  70. Han YH, Sweet DH, Hu DN, Pritchard JB. 2001. Characterization of a novel cationic drug transporter in human retinal pigment epithelial cells. J. Pharmacol. Exp. Therapeu. 296: 450-7.

    CAS  Google Scholar 

  71. Hansen CB, Kao GY, Moase EH, Zalipsky S, Allen TM. 1995. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparision and optimization of coupling procedures. Biochi Biophys Acta 856: 556-81.

    Google Scholar 

  72. Harada A, Kataoka K. 1998. Novel polyion complex micelles entrapping enzyme molecules in the core: preparation of narrowly-distributed micelles from lysozyme and poly(ethylene glycol)-poly(aspartic acid) block copolymer in aqueous medium. Macromolecules 31: 288-94.

    CAS  Google Scholar 

  73. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Abra RM, Uster PS, et al., 2000. Influence of tumor size on uptake of 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model. Brit. J. Cancer 83: 684-8.

    CAS  PubMed  Google Scholar 

  74. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Uster PS, Abra RM, Stewart JSW. 2000. Biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies. Brit. J. Cancer 83: 232-8.

    CAS  PubMed  Google Scholar 

  75. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Uster PS, Vile RG, Stewart JSW. 2000. Pegylated liposomes have potential as vehicles for intratumoral and subcutaneous drug delivery. Clinical Cancer Res. 6: 2528-37.

    CAS  Google Scholar 

  76. Hayashi H, Kono K, Takagishi T. 1999. Temperature sensitization of liposomes using copolymers of N-isopropylacrylamide. Bioconjugate Chem 10: 412-8.

    CAS  Google Scholar 

  77. Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM. 2003. Domain antibodies: proteins for therapy. Trends Biotechnol. 21: 484-90.

    CAS  PubMed  Google Scholar 

  78. Houshamand P, Zlotnik A. 2003. Targeting tumor cells. Curr. Opin. Cell Biol. 15: 640-4.

    Google Scholar 

  79. Ishida O, Maruyama K, Tanahashi H, Iwatsuru M, Sasaki K, et al., 2001. Liposome bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharmaceut. Res. 18: 1042-8.

    CAS  Google Scholar 

  80. Ishida T, Iden DL, Allen TM. 1999. A combinatorial approach to producing sterically stabilized (stealth) immunoliposomal drugs. FEBS Lett. 460: 129-33.

    CAS  PubMed  Google Scholar 

  81. Jain RK. 1999. Transport of molecules, particles, and cells in solid tumors. Annu. Rev. Biomed. Eng. 1: 241-63.

    CAS  PubMed  Google Scholar 

  82. Jain RK. 2001. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 46: 149-68.

    CAS  PubMed  Google Scholar 

  83. Janknegt R, vanEtten EWM, deMarie S. 1996. Lipid formulations of amphotericin B. Curr Opin Infect Dis 9: 403-6.

    Google Scholar 

  84. Johnsson M, Bergstrand N, Edwards K. 1999. Optimization of drug loading procedures and characterization of liposomal formulations of two novel agents intended for boron neutron capture therapy (BNCT). J Liposome Res 9: 53-79.

    CAS  Google Scholar 

  85. Johnstone SA, Masin D, Mayer L, Bally MB. 2001. Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages. Biochim. Biophys. Acta 1513: 25-37.

    CAS  PubMed  Google Scholar 

  86. Jung BH, Chung BC, Chung S, Lee M, Shim C. 2000. Prolong delivery of nicotine in rats via nasal administration of proliposomes. J. Contralled Release 66: 73-9.

    CAS  Google Scholar 

  87. Jung BH, Chung BC, Chung S, Shim C. 2001. Different pharmacokinetics of nicotine followig intravenous administration of nicotine base and nicotine hydrogen tartarate in rats. J. Contralled Release 77: 183-90.

    CAS  Google Scholar 

  88. Jung BH, Chung SJ, Shim CK. 2002. Proliposomes as prolonged intranasal drug delivery systems. STP Pharma Sci. 1: 33-8.

    Google Scholar 

  89. Kataoka K. 1997. Targetable polymeric drugs. In Controlled drug delivery: challenges and strategies., ed. K Park, pp. 49-71. Washington D.C.: American Chemical Society.

    Google Scholar 

  90. Kataoka K, Harada A, Nagasaki Y. 2001. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev. 47: 113-31.

    CAS  PubMed  Google Scholar 

  91. Kato E, Taguchi A, Sakashita S, Akiyoshi K, Sunamoto J. 2000. Synthesis and function of sialic acid-conjugated cholesterols as ganglioside analogs: their reconstitution to liposomes and interaction with rat lymphocytes. Proc. Japan Acad. 76 B: 63-7.

    Google Scholar 

  92. Kavanagh BD, Secomb TW, Hsu R, Lin P, Venitz J, Dewhirst MW. 2002. A theoretical model for the effects of reduced hemoglobin-oxigen affinity on tumor oxygenation. Int. J. radiation Oncology Biol. Phys. 53: 172-9.

    CAS  Google Scholar 

  93. Kawakami S, Munakata C, Fumoto S, Yamashita F, Hashida M. 2000. Targeted delivery of prostaglandin E1 to hepatocytes using galactosylated liposomes. J. Drug Targeting 8: 137-42.

    CAS  Google Scholar 

  94. Kennedy RR, French RA, Spencer C. 2002. Predictive accuracy of a model of volatile anesthetic uptake. Anesth. Analg. 95: 1616-21.

    CAS  PubMed  Google Scholar 

  95. Kerns EH, Di L. 2003. Pharmaceutical profiling in drug discovery. DDT 8: 316-23.

    CAS  PubMed  Google Scholar 

  96. Khandurina J, Guttman A. 2002. Microchip-based high-throughput screening analysis of combinatorial libraries. Curr. Opin. Chem. Biol. 6: 359-66.

    CAS  PubMed  Google Scholar 

  97. Khanvilkar K, Donovan MD, Flanagan DR. 2001. Drug transfer through mucus. Adv. Drug Deliv. Rev. 48: 173-93.

    CAS  PubMed  Google Scholar 

  98. Kim CK, Jeong EJ, Kim MH. 2000. Comparision of in vivo fate and immunogenicity of hepatitis B surface antigen incorporated in cationic and neutral liposomes. J. Microencapsulation 17: 297-306.

    PubMed  Google Scholar 

  99. Koivunen E, arap W, Valtanen H, Haininsalo A, Pebate-Medina O, et al., 1999. Cancer therapy with a novel tumor-targeting gelatinase inhibitor selected by phage peptide display. Nat. Biotechnol. 17: 768-74.

    CAS  PubMed  Google Scholar 

  100. Koivunen E, Ranta TM, Annila A, Taube S, Uppala A, et al., 2001. Inhibition of beta(2) integrin-mediated leukocyte cell adhesion by leucine-leucine-glycine motif-contaning peptides. J. Cell. Biol. 153: 905-16.

    CAS  PubMed  Google Scholar 

  101. Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, et al., 2000. Efficiency of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res. 60: 6950-7.

    CAS  PubMed  Google Scholar 

  102. Kono K, Nakai R, Morimoto K, Takagishi T. 1999. Thermosensitive polymer-modified liposomes that release contents around physiological temperature. Biochim Biophys Acta 1416: 239-50.

    CAS  PubMed  Google Scholar 

  103. Krause W. 1999. Delivery of diagnostic agents in computed tomography. Adv Drug Delivery Rev 37: 159-73.

    CAS  Google Scholar 

  104. Kurz M, Scriba GKE. 2000. Drug-phospholipid conjugates as potential prodrugs: synthesis, characterization, and degradation by pancreatic phospholipase A2. Chem. Phys. Lipids 107: 143-57.

    CAS  PubMed  Google Scholar 

  105. Kwon GS, Okano T. 1996. Polymeric micelles as new drug carriers. Adv. Drug. Delivery. Rev. 21: 107-16.

    CAS  Google Scholar 

  106. Lacasse FX, Filion MC, Phillips NC, Escher E, McMullen JN, Hilden P. 1998. Influence of surface properties at biodegradable microsphere surfaces: effects on plasma protein adsorption and phagocytosis. Pharm Res 15: 312-7.

    CAS  PubMed  Google Scholar 

  107. Langner M. 2000. Effect of liposome molecular composition on its ability to carry drugs. Polish J Pharmacol 52: 3-14.

    CAS  Google Scholar 

  108. Langner M. 2000. The intracellular fate of non-viral DNA carriers. Cell. Molec. Biol. Lett. 5: 295-313.

    CAS  Google Scholar 

  109. Langner M, Kral T. 1999. Liposome-based drug delivery systems. Pol J Pharmacol 51: 211-22.

    CAS  PubMed  Google Scholar 

  110. Lasic DD. 1996. Doxorubicin in sterically stabilized liposomes. Nature 380: 5611-20.

    Google Scholar 

  111. Lasic DD. 1997. Recent developments in medical applications of liposomes: sterically stabilized liposomes in cancer therapy and gene delivery in vivo. J Contr Rel 48: 203-22.

    CAS  Google Scholar 

  112. Lasic DD, Needham D. 1995. The “Stealth” Liposome: a prototypical biomaterial. Chem Rev 95: 2601-34.

    CAS  Google Scholar 

  113. Lazar GA, Marshall SA, Plecs JJ, Mayo SL, Desjarlais JR. 2003. Designing proteins for therapeutic applications. Curr. Opin. Struct. Biol. 13: 513-9.

    CAS  PubMed  Google Scholar 

  114. Leitzke S, Bucke W, Borner K, Muller R, Hahn H, Ehlers S. 1998. Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection. Antimicrob Agents Chemother 42: 459-61.

    CAS  PubMed  Google Scholar 

  115. Leslie SB, Puvvada S, Ratna BR, Rudolph AS. 1996. Encapsulation of hemoglobin in a bicontinuous cubic phase lipid. Biochim Biophys Acta 1285: 246-54.

    CAS  Google Scholar 

  116. Lestini BJ, Sagnella SM, Xu Z, Shive MS, Richter NJ, et al., 2003. Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery. J. Controlled Release 78: 235-47.

    Google Scholar 

  117. Lian T, Ho RJY. 2001. Trends and developments in liposome drug delivery systems. J. Pharmaceut. Sci. 90: 667-80.

    CAS  Google Scholar 

  118. Liaw J, Aoyagi T, Kataoka K, Sakurai Y, Okano T. 1999. Permeation of PEO-PBLA-FITC polymeric micelles in aortic endothelial cells. Pharm Res 16: 213-20.

    CAS  PubMed  Google Scholar 

  119. Lohmann C, Huwel S, Galla HJ. 2002. Predicting blood-brain barrier permeability of drugs: evaluation of different in vitro assays. J. Drug Targeting 10: 263-76.

    CAS  Google Scholar 

  120. Loidl-Stahlhofen A, Eckert A, Hartmann T, Schottner M. 2001. Solid-supported lipid membranes as a tool for determination of membrane affinity: high-throughput screening of a physicochemical parameters. J. Pharmaceut. Sci. 90: 599-606.

    CAS  Google Scholar 

  121. Loidl-Stahlhofen A, Hartmann T, Schottner M, Rohring C, Brodowsky H, et al., 2001. Multilamellar liposomes and solid-supported lipid membranes (TRANSIL): screening  of lipid-water partitioning toward a high-throughput scale. Pharmaceut. Res. 18: 1782-8.

    CAS  Google Scholar 

  122. Lopes-de-menezes DE, Pilarski LM, Belch AR, Allen TM. 2000. Selective targeting of immunoliposomeal doxorubicin against human multiple myeloma in vitro and ex vivo. Biochim. Biophys. Acta 1466: 205-20.

    CAS  PubMed  Google Scholar 

  123. Mager DE, Jusko WJ. 2002. Quantitative structure-pharmacokinetic/pharmacodynamic relationship of corticosteroids in man. J. Pharmaceut. Sci. 91: 2441-51.

    CAS  Google Scholar 

  124. Makabi-Panzu B, Gourde P, Desormeaux A, Bergeron MG. 1998. Intracellular and serum stability of liposomal 2’,3’-dideoxycytidine. Effect of lipid composition. Cell Mol Biol 44: 277-84.

    CAS  PubMed  Google Scholar 

  125. Makino K, Yamamoto N, Higuchi K, Harada N, Ohshima H, Terada H. 2003. Phagocytic uptake of polystyrene microspheres by alveolar macrophages: effect of the size and surface properties of the microspheres. Colloids and SUrface B: Biointerfaces. 27: 33-9.

    CAS  Google Scholar 

  126. Mannhold R, van-de-Waterbeemd H. 2001. Substructure and whole molecule approaches for calculating logP. J. Computer-Aided Molec. Design 15: 337-54.

    CAS  Google Scholar 

  127. Marcucci F, Lefoulon F. 2004. Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress. DDT 9: 219-28.

    CAS  PubMed  Google Scholar 

  128. McGinnity DF, Riley RJ. 2001. Predicting drug pharmacokinetics in human from in vitro metabolism studies. Biochem. Soc. Trans. 29: 135-40.

    CAS  PubMed  Google Scholar 

  129. McIntosh DP, Tan X, Oh P, Schnitzer JE. 2002. Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. PNAS 99: 1996-2001.

    CAS  PubMed  Google Scholar 

  130. Mehta J, Kelsey S, Chu P, Powles R, Hazel D, et al., 1997. Amphotericin B lipid complex (ABLC) for the treatement of confirmed or presume fungal infections in immunocompromised patients with hematologic malignancies. Bone Marrow Transplant 20: 39-43.

    CAS  PubMed  Google Scholar 

  131. Meilander NJ, Yu X, Ziats NP, Bellamkonda RV. 2001. Lipid-based microtubular drug delivery vehicles. J. Controlled Release 71: 141-52.

    CAS  Google Scholar 

  132. Miller AD. 1998. Cationic liposomes for gene therapy. Angew. Chem. Int. Ed. 37: 1768-85.

    Google Scholar 

  133. Mills JK, Needham D. 1999. Targeted drug delivery. Exp Opin Ther Patents 9: 1499-513.

    Google Scholar 

  134. Miyamoto M, Hirano K, Ichikawa H, Fukumori Y, Akine Y, Tokuuye K. 1999. Preparation of gadolinium-containing emulsions stabilized with phosphatidylcholine-surfactant mixtures for neutron-capture therapy. CHem Pharmaceut Bull 47: 203-8.

    CAS  Google Scholar 

  135. Moghimi SM, Patel HM. 2002. Modulation of murine liver macrophage clearance of liposomes by diethylstilbestrol. The effect of vesicle surface charge and a role for the complement receptor Mac-1 (CD11b/CD18) of newly recruited macrophages in liposome recognition. J. Controlled Release 78: 55-65.

    CAS  Google Scholar 

  136. Mosqueira VCF, Legrand P, Morgat J-L, Vert M, Mysiakine E, et al., 2001. Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effect of PEG chain length and density. Pharmaceut. Res. 18: 1411-9.

    CAS  Google Scholar 

  137. Nakanishi T, Kunisawa J, Hayashi A, Tsutsumi Y, Kubo K, et al., 1999. Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins. J Controlled Release 61: 233-40.

    CAS  Google Scholar 

  138. Nightingale SD, Saletin SL, Swenson CE, Lawrence AJ, Watson DA, et al., 1993. Liposome-encapsulated gentamicin treatement of Mycobacterium avium-Mycobacterium intracellulare complex bacteremia in AIDS patients. Antymicrob Agents Chemother 37: 1869-72.

    CAS  Google Scholar 

  139. Nishioka Y, Yoshino H. 2001. Lymphotic targeting with nanoparticulate system. Adv. Drug Deliv. Rev. 47: 55-64.

    CAS  PubMed  Google Scholar 

  140. Oh YK, Nix DE, Straubinger RM. 1995. Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection. Antimicrob Agents Chemother 39: 2104-11.

    CAS  PubMed  Google Scholar 

  141. Oja CD, Semple SC, Chonn A, Cullis PR. 1996. Influence of dose on liposome clearance: critical role of blood proteins. Biochim Biophys ACta 1281: 31-7.

    PubMed  Google Scholar 

  142. Opanasopit P, Higuchi Y, Kawakami S, Yamashita F, Nishikawa M, Hashida M. 2001. Involvement of serum mannan binding protein and mannose receptors in uptake of mannosylated liposomes by macrophages. Biochim. Biophys. Acta 1511: 134-45.

    CAS  PubMed  Google Scholar 

  143. Oussoren C, Storm G. 1999. Role of macrophages in the localisation of liposomes in lymph nodes after subcutaneous administration. Internatl. J. Pharmaceutics 183: 37-41.

    CAS  Google Scholar 

  144. Oussoren C, Zuidema J, Crommelin DJA, Storm G. 1997. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid composition and lipid dose. Biochim Biophys Acta 1328: 261-72.

    CAS  PubMed  Google Scholar 

  145. Panetta JC, Yanishevski Y, Pui CH, Sandlund JT, Rubnitz J, et al., 2002. A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. Cancer Chemother. Pharmacol. 50: 419-28.

    CAS  Google Scholar 

  146. Papahadjopoulos D. 1996. Fate of liposomes in vivo: a brief introductory review. J. Liposome Res 6: 3-17.

    Google Scholar 

  147. Parr MJ, Masin D, Cullis PR, Bally MB. 1997. Accumulation of liposomal lipid and encapsulated doxorubicin in Murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). J Pharm Exp Therapetics 280: 1319-27.

    CAS  Google Scholar 

  148. Patnum D, Kopecek J. 1995. Polymer conjugates with anticancer activity. Adv Polymer Sci 122: 55-123.

    Google Scholar 

  149. Paulos CM, Turk MJ, Breur GJ, Low PS. 2004. Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv. Drug Deliv. Rev. 56: 1205-17.

    CAS  PubMed  Google Scholar 

  150. Prego C, Garcia M, Torres D, Alonso MJ. 2005. Transmucosal macromolecular drug delivery. J. Controlled Release 101: 151-62.

    CAS  Google Scholar 

  151. Rausch JM, Wimley WC. 2001. A high-throughput screen for identifying transmembrane pore-forming peptides. Analyt. Biochem. 293: 258-63.

    CAS  PubMed  Google Scholar 

  152. Rechlaender BN, Cho MJ. 2001. Antibodies as drug carriers. I. For proteins. Pharmaceut. Res. 18: 753-60.

    Google Scholar 

  153. Rechlaender BN, Cho MJ. 2001. Antibodies as drug carriers. II. For small molecules. Pharmaceut. Res. 18: 745-52.

    Google Scholar 

  154. Rensen PCN, de-Vrueh RLA, Kuiper J, Bijsterbosch MK, Biessen EAL, van-Berkel TJC. 2001. Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv. Drug Deliv. Rev. 47: 251-76.

    CAS  PubMed  Google Scholar 

  155. Rui Y, Wang S, Low PS, Thompson DH. 1998. Diplasmenylcholine-folate liposomes: An efficient vehicle for intracellular drug delivery. J Amer Chem Soci 120: 11213-8.

    CAS  Google Scholar 

  156. Saari M, Vidgren MT, Koskinen MO, Turjanmaa VMH, Niminen MM. 1999. Pulmonary distribution and clearance of two beclomethasone liposome formulations in healthy volunteers. Inter J Pharm 181: 1-9.

    CAS  Google Scholar 

  157. Sachetelli S, Beaulac C, Riffon R, Lagace J. 1999. Evaluation of the pulmonary and systemic immunogenicity of fluidosomes, a fluid liposomal-tobramycin formulation for the treatment of chronic infections in lungs. Biochim Biophys Acta 1428: 334-40.

    CAS  PubMed  Google Scholar 

  158. Saul JM, Annapragada A, Natarajan JV, Bellamkonda RV. 2003. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J. Controlled Release 92: 49-67.

    CAS  Google Scholar 

  159. Savay S, Szebeni J, Baranyi L, Alving CR. 2002. Potentiation of liposome-induced complement activation by surface-bound albumin. Biochim. Biophys. Acta 1559: 79-86.

    CAS  PubMed  Google Scholar 

  160. Savva M, Duda E, Huang L. 1999. A genetically modified recombinant tumor necrosis factor-a conjugated to the distal terminals of liposomal surface grafted polyethylene-glycol chains. Internal J Pharmaceut 184: 45-51.

    CAS  Google Scholar 

  161. Scherphof GL, Kamps JAAM. 2001. The role of hepatocytes in the clearance of liposomes from the blood circulation. Progress Lipid Res. 40: 149-66.

    CAS  Google Scholar 

  162. Senchenkov A, Litvak DA, Cabot MC. 2001. Targeting ceramide metabolism - a strategy for overcoming drug resistance. J. Natl. Cancer Inst. 93: 347-57.

    CAS  PubMed  Google Scholar 

  163. Spragg DD, Alford DR, Greferath R, Larsen CE, Lee KD, et al., 1997. Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selective delivery in the cardiovascular system. Proc Natl Acad Sci USA 94: 8795-800.

    CAS  PubMed  Google Scholar 

  164. Storm G, Bakker-Woudenberg IAJM, Schiffelers RM, Oyen WJG, Crommelin DJA, et al., 1998. Diagnostic and therapeutic targeting of infections and inflamatary diseases using sterically stabilized liposomes. In Targeting of Drugs 6: Strategies for Stealth Therapeutic System., ed. Gregoriadis, McCormack, pp. 121-30. New York: Plenum Press.

    Google Scholar 

  165. Storm G, Crommelin DJA. 1998. Liposomes: quo vadis? PSTT 1: 19-31.

    CAS  Google Scholar 

  166. Storni T, Kundig TM, Senti G, Johansen P. 2005. Immunity in response to particulate antigen-delivery systems. Adv. Drug Delivery Rev. 57: 333-55.

    CAS  Google Scholar 

  167. Sugano K, Hamada H, Machida M, Ushio H. 2001. High throughput prediction of oral adsorption: improvement of the composition of the lipid solution used in parallel artificial membrane permeability assay. J. Biomolecular Screening 6: 189-96.

    CAS  Google Scholar 

  168. Szebeni J, Baranyi L, Savay S, Lutz HU, Jelezarova E, et al., 2000. The role of complement activation in hypersensitivity to pegylated liposomal Doxorubicin (DOXIL). J. Liposome Res. 10: 467-81.

    CAS  Google Scholar 

  169. Tardi PG, Boman NL, Cullis PR. 1996. Liposomal doxorubicin. J Drug Targeting 4: 129-40.

    CAS  Google Scholar 

  170. Taylor DL, Woo ES, Giuliano KA. 2001. Real-time molecular and cellular analysis: the new frontier of drug discovery. Curr. Opin. Biotechnol. 12: 75-81.

    CAS  PubMed  Google Scholar 

  171. Temsamani J, Vidal P. 2004. The use of cell-penetrating peptides for drug delivery. DDT 23: 1012-9.

    Google Scholar 

  172. Testa B. 1997. Drugs as chemical messages: molecular sytructure, biological context, and structure-activity relationship. Med. Chem. Res. 7: 340-65.

    CAS  Google Scholar 

  173. Thole M, Nobmann S, Huwyler J, Fricker G. 2002. Uptake of cationized albumin coupled liposomes by cultured porcine brain microvessel endothelial cells and intact brain capillaries. J. Drug Targeting 10: 337-44.

    CAS  Google Scholar 

  174. Torchilin VP. 2001. Structure and design of polymeric surfactant-based drug delivery systems. J. Controlled Release 73: 137-72.

    CAS  Google Scholar 

  175. Torchilin VP, Lukyanov AN. 2003. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov. Today 8: 259-66.

    CAS  Google Scholar 

  176. Tozer GM, Ameer-Beg SM, Baker J, Barber PR, Hill SA, et al., 2005. Intravital imaging of tumor vascular networks using multi-photon fluorescence microscopy. Adv. Drug Deliv. Rev. 57: 135-52.

    CAS  PubMed  Google Scholar 

  177. Trail PA, Bianchi AB. 1999. Monoclonal antibody drug conjugates in the treatment of cancer. Curr Opin Immunol 11: 584-8.

    CAS  PubMed  Google Scholar 

  178. Ulbrich K, Subr V. 2004. Polymeric anticancer drugs with pH-controlled activation. Adv Drug Deliv Rev 56: 1023-50.

    CAS  PubMed  Google Scholar 

  179. Unger EC, Porter T, Culp W, Labell R, Matsunaga T, Zutshi R. 2004. Therapeutic applications of lipid-coated microbubbles. Adv. Drug. Deliv. Rev. 56: 1291-314.

    CAS  PubMed  Google Scholar 

  180. van-de-Waterbeemd H, Smith DA, Beaumont K, Walker DK. 2001. Property-based design: optimization of drug absorption and pharmacokinetics. J. Med. Chem. 44: 1313-33.

    CAS  PubMed  Google Scholar 

  181. van-Slooten KL, Storm G, Zoephel A, Kupcu Z, Boerman O, et al., 2000. Liposomes containing interferon-gamma as adjuvant in tumor cell vaccines. Pharmaceut. Res. 17: 42-8.

    CAS  Google Scholar 

  182. van-Slooten ML, Boerman O, Romoren K, Kedar E, Crommelin DJA, Storm G. 2001. Liposomes as sustained release system for human interferon-g biopharmaceutical aspects. Biochim. Biophys. Acta 1530: 134-45.

    CAS  PubMed  Google Scholar 

  183. van-Slooten ML, Kircheis R, Koppenhagen FJ, Wagner E, Storm G. 1999. Liposomes as cytokine-supplement in tumor cell-based vaccines. Int. J. Pharmaceutics 183: 33-6.

    CAS  Google Scholar 

  184. van-Zuylen L, Karlsson MO, Verweij J, Brouwer E, de-Bruijn P, et al., 2001. Pharmacokinetic modeling of paclitaxal encapsulation in cremophor EL micelles. Cancer Chemother. Pharmacol. 47: 309-18.

    CAS  Google Scholar 

  185. Velpandian T, Gupta SK, Gupta YK, Biswas NR, Agarwal HC. 1999. Ocular drug targeting by liposomes and their corneal interactions. J Microencapsulation 16: 243-50.

    CAS  PubMed  Google Scholar 

  186. Veng-Pedersen P. 2001. Noncompartmentally-based pharmacokinetic modeling. Adv. Drug Deliv. Rev. 48: 265-300.

    CAS  PubMed  Google Scholar 

  187. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, et al., 1998. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clinic Infect Disease 26: 1383-96.

    CAS  Google Scholar 

  188. Watabe A, Yamaguchi T, Kawanishi T, Uchida E, Eguchi A, et al., 1999. Target-cell specificity of fusogenic liposomes: membrane fusion-mediated macromolecule delivery into human blood mononuclear cells. Biochim Biophys Acta 1416: 339-48.

    CAS  PubMed  Google Scholar 

  189. Watson P, Jones AT, Stephens DJ. 2005. Intracellular trafficking pathways and drug delivery: fluorescence imaging of living and fixed cells. Adv. Drug Deliv. Rev. 57: 43-61.

    CAS  PubMed  Google Scholar 

  190. Watt AP, Morrison D, Evans DC. 2000. Approaches to higher-throughput pharmacokinetics (HTPK) in drug discovery. DDT 5: 17-24.

    CAS  PubMed  Google Scholar 

  191. White RE. 2000. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu. Rev. Pharmacol. Taxicol. 40: 133-57.

    CAS  Google Scholar 

  192. Working PK. 1999. Amphotericin B colloidal dispersion. Chemotherapy 45: 15-26.

    CAS  PubMed  Google Scholar 

  193. Wright JG, Boddy AV. 2001. All half-lives are wrong, but some half-lifes are useful. Clin. Pharmacokinet. 40: 237-44.

    CAS  PubMed  Google Scholar 

  194. Yanagihara K, Kato E, Hitomi S, Sunamoto J, Wada H. 1999. Activation of human T lymphocytes by ganglioside-containing liposomes. Glycoconjugate J 16: 59-65.

    CAS  Google Scholar 

  195. Yang SC, Benita S. 2000. Enhanced adsorption and drug targeting by positively charged submicron emulsions. Deug Dev. Res. 50: 476-86.

    CAS  Google Scholar 

  196. Ye Q, Asherman J, Stevenson M, Brownson E, Katre NV. 2000. DepoFoamTM technology: a vehicle for controlled delivery of protein and peptide drugs. J. Controlled Release 64: 155-66.

    CAS  Google Scholar 

  197. You J, Kamihira M, Iijima S. 1998. Enhancement of transfection efficiency using ligand-modified lipid vesicles. J Ferment Bioengineer 5: 525-8.

    Google Scholar 

  198. Yu H, Adedoyin A. 2003. ADME-Tox in drug discovery integration of experimental and computational technologies. Drug Disc. Today 8: 852-61.

    CAS  Google Scholar 

  199. Zalipsky S, Gittelman J, Mullah N, Qazen MM, Harding JA. 1998. Biologically active ligand-bearing polymer-grafted liposomes. In Strategies for Stealth Therapeutic Systems., ed. Ga McCormack. New York: Plenum Press.

    Google Scholar 

  200. Zarif L, Graybill JR, Perlin D, Mannino RJ. 2000. Cochleates: new lipid-based drug delivery systems. J. Liposome Res. 10: 523-38.

    CAS  Google Scholar 

  201. Zasadzinski JA, Kisak E, Evans C. 2001. Complex vesicle-based structures. Curr. Opin. Coll. Interface Sci. 6: 85-90.

    CAS  Google Scholar 

  202. Zelphati O, Wang Y, Kitada S, Reed JC, Felgner PL, Corbeil J. 2001. Intracellular delivery of proteins with a new lipid-mediated delivery system. J. Biol. Chem. 276: 35103-10.

    CAS  PubMed  Google Scholar 

  203. Zheng L, Huang XL, Fan Z, Borowski L, Wilson CC, Rinaldo CR. 1999. Delivery of liposome-encapsulated HIV type 1 proteins to human dendritic cells for stimulation of HIV type 1-specific memory cytotoxic T lymphocyte tesponses. AIDS Res Hum Retrovir 15: 1011-20.

    CAS  PubMed  Google Scholar 

  204. Zhou WZ, Kaneda Y, Huang SKS, Mrishita R, Hoon DSB. 1999. Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine. Gene Therapy 6: 1768-73.

    CAS  PubMed  Google Scholar 

  205. Zuideveld KP, van-Gestel A, Peletier LA, van-der-Graff PH, Danhof M. 2002. Pharmacokinetic-pharmacodynamic modelling of the hypothermic and corticosterone effects of the 5-HT1A receptor agonist flesinocan. Eur. J. Pharmacol. 445: 43-54.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2006 Springer

About this chapter

Cite this chapter

Langner, M., Kozubek, A. (2006). Pharmacokinetic Modulation with Particulate Drug Formulations. In: Mozafari, M.R. (eds) Nanocarrier Technologies. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-5041-1_8

Download citation